Genmab And Seagen Announced TIVDAK Significantly Prolonged Overall Survival In Patients with Recurrent Or Metastatic Cervical Cancer Compared With Chemotherapy In Global Phase 3 innovaTV 301 Trial
Portfolio Pulse from Charles Gross
Genmab A/S (GMAB) and Seagen Inc. (SGEN) announced additional results from the Phase 3 innovaTV 301 trial, showing that TIVDAK significantly reduced the risk of death in recurrent or metastatic cervical cancer patients compared to chemotherapy. The results were presented at the European Society of Medical Oncology Congress 2023.
October 22, 2023 | 2:45 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Genmab's TIVDAK showed promising results in Phase 3 trial, potentially boosting its market position in cancer treatment.
The positive results from the Phase 3 trial of TIVDAK could potentially boost Genmab's market position in cancer treatment. This could lead to increased sales and revenue for the company, positively impacting its stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100
POSITIVE IMPACT
Seagen's TIVDAK showed promising results in Phase 3 trial, potentially boosting its market position in cancer treatment.
The positive results from the Phase 3 trial of TIVDAK could potentially boost Seagen's market position in cancer treatment. This could lead to increased sales and revenue for the company, positively impacting its stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100